Abatacept for lung disease in people with common variable immunodeficiency (GLILD)
Official title: Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20
Funded at Cincinnati Childrens Hosp Med Ctr · NIH-11261089 · Data updated 2026-11-12
This compares abatacept with a placebo to see whether abatacept can improve the lung disease (GLILD) that can occur in people with CVID.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | September 10, 2021 |
| Project end | December 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $756,873 |
| NIH project number | 5R01FD007267-04 |
| Project ID | NIH-11261089 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people diagnosed with common variable immunodeficiency (CVID) who have GLILD and meet the study’s eligibility requirements.
✕Less likely to help
People with CVID who do not have GLILD, or those with active infections or other medical reasons that make abatacept unsafe, are unlikely to benefit from this trial.
What this research studies
If you have CVID with granulomatous-lymphocytic interstitial lung disease (GLILD), this trial will randomly give participants either the drug abatacept or a placebo without telling them which for six months, followed by a six-month phase when everyone can receive abatacept. Abatacept is a biologic medicine that works by blocking T cell activation through CTLA-4 binding to CD80/CD86. The team previously saw improvement in a small group of patients and now plans a blinded, controlled approach to measure benefits and risks more clearly. The trial is led from Cincinnati Children’s Hospital and uses clinical visits and monitoring over the treatment periods.
Why it matters
Potential benefit: If successful, abatacept could reduce lung inflammation from GLILD and improve breathing and quality of life for people with CVID.
How similar studies have gone: Small case series have reported good responses to abatacept in patients with CVID-related GLILD, but this is the first rigorous randomized, blinded trial to test it.
Where this research is happening
-
Cincinnati Childrens Hosp Med Ctr
Cincinnati, United States Active
Researchers
- Principal investigator: Jordan, Michael — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Jordan, Michael
Related research
Other NIH-funded projects on the same topics.
-
Using abatacept to treat lung disease in patients with common variable immunodeficiency.
This study is looking at how well a medication called abatacept can help improve lung health in people with common variable immunodeficiency who have a specific lung condition, and it involves trying the drug for six months to see how it works.
-
Obinutuzumab for CTD-Related Interstitial Lung Disease in adults
This project tests whether the anti-B cell therapy obinutuzumab can help adults with connective tissue disease–related ILD who are on mycophenolate therapy.
-
Obinutuzumab for connective tissue disease–related interstitial lung disease in adults
A study will test whether Obinutuzumab, given with standard treatments, can help adults with CTD-ILD breathe better and have fewer disease-related problems.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Understanding how a cell protein (SLC9A1) drives skin and lung scarring in systemic sclerosis
A five-year NIH grant aims to understand how a specific cell protein called SLC9A1 influences scar-forming cells in systemic sclerosis and related lung disease, with the goal of finding possible therapies.
-
Sustained antibody delivery to durably control HIV-1
A project aims to use gene-delivered antibodies to control HIV-1 for a long time without daily pills.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.